a lot of the late stage AD companies have gotten quiet after the bapi/sola negative storm.
I noticed gantenerumab has finished their phase 3 recruitment in prodromal AD. Results should be available in 2016. That will be the next big trial to read out.
the earliest a new therapy could come to market is 2017.
solanezumab and crenezumab and MK-8931 results will probably be in 207 or 2018.
anyone who already has symptomatic AD will unfortunately not have a chance to be helped with these products, if any of the compunds make it.
News 
Market Data 
Discover 
